Pylarify drug
Ended Awarded Last action
- Contract number
- 36C25524N0212
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 15
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $230,958
Award facts
- Contract value 100% obligated
- $230,958.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lemay Township, MO 63125, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $41,958 | |
| Original award | $189,000 |
About this award
This federal contract award is for the delivery of PYLARIFY (piflufolastat F-18), a radiopharmaceutical product used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The contract, valued at $230,958.08, was awarded to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The contract is a Blanket Purchase Agreement (BPA) call under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), facilitated by the Department of Veterans Affairs (VA) and the Defense Health Agency (DHA). This contract is not set aside. Progenics Pharmaceuticals is a pharmaceutical company specializing in innovative medicines and artificial intelligence solutions for the diagnosis and treatment of cancer and other diseases. The VA and DHA are the primary federal healthcare providers procuring PYLARIFY and other radiopharmaceuticals from Progenics Pharmaceuticals to support their medical imaging programs at various facilities.
Quick answers
Who was awarded contract 36C25524N0212?
36C25524N0212 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 15 (Veterans Health Administration) on March 1, 2024.
How much is contract 36C25524N0212 worth?
The government has obligated $230,958 on 36C25524N0212.
Is contract 36C25524N0212 an order under another contract?
Yes. 36C25524N0212 is a BPA call under 36F79719D0170-36C25523A0018, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25524N0212 competed?
The extent of competition for 36C25524N0212 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award